Stock A200230 TELCON RF PHARMACEUTICAL. INC.
Add to a list
To use this feature you must be a member
Log inSign up

News TELCON RF PHARMACEUTICAL. Inc.

Equities

A200230

KR7200230001

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
783 KRW +3.71% Intraday chart for TELCON RF PHARMACEUTICAL. Inc. +5.67% -10.31%
Apr. 19 TELCON RF PHARMACEUTICAL. Inc. announced that it has received KRW 22 billion in funding from Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd. CI
Apr. 19 Abion Inc. announced that it has received KRW 19 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
TELCON RF PHARMACEUTICAL. Inc. announced that it has received KRW 22 billion in funding from Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.
CI
Abion Inc. announced that it has received KRW 19 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank
CI
TELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 22 billion in funding from Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.
CI
Abion Inc. announced that it expects to receive KRW 19 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank
CI
Abion Inc. announced that it has received KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc.
CI
TELCON RF PHARMACEUTICAL. Inc. announced that it has received KRW 6 billion in funding from Abion Inc.
CI
TELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 6 billion in funding from Abion Inc.
CI
Abion Inc. announced that it expects to receive KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc.
CI
TELCON RF PHARMACEUTICAL. Inc.(KOSDAQ:A200230) dropped from S&P Global BMI Index
CI
TELCON RF PHARMACEUTICAL. Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
TELCON RF PHARMACEUTICAL. Inc. Auditor Raises 'Going Concern' Doubt
CI
KPM TECH Co., Ltd. announced that it has received KRW 9.99999925 billion in funding from TELCON RF PHARMACEUTICAL. Inc.
CI
KPM TECH Co., Ltd. announced that it expects to receive KRW 9.99999925 billion in funding from TELCON RF PHARMACEUTICAL. Inc.
CI
Humanigen’s Partner in South Korea Receives Ministry of Food and Drug Safety Approval to Conduct Phase 1 Study of Lenzilumab
CI
Humanigen, Inc Announces the Execution of Licensing Agreement with Telcon Rf Pharmaceutical, Inc. and KPM Tech Co., Ltd
CI
Telcon RF Pharmaceutical Inc. announced that it has received KRW 40.65 billion in funding from Hanil Vacuum Co., Ltd.
CI
Telcon RF Pharmaceutical Inc. acquired an additional 9.97% stake in KPM TECH Co., Ltd. from Evercore Investment Corp. for KRW 47.9 billion.
CI
Telcon RF Pharmaceutical Inc. announced that it has received KRW 30 billion in funding from Emmaus Life Sciences, Inc.
CI
TELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 30 billion in funding from Emmaus Life Sciences, Inc.
CI
TELCON RF PHARMACEUTICAL. Inc. acquired an additional 3.73% stake in Abion Inc. from Leeds Investments Inc. and an individual for KRW 2.8 billion.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A200230 Stock
  4. News TELCON RF PHARMACEUTICAL. Inc.